netFormulary
 Report : Medicines with links to NICE 28/05/2020 15:51:20

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Adalimumab 01.05.03 Formulary NICE TA187: Infliximab and adalimumab for the treament of Crohns disease
Anti-D (Rh0) Immunoglobulin 14.05.03 Formulary NICE TAG156: Anti-D in pregnant women
Azacitidine 08.01.03 Formulary NICE TA218: azacitidine for myelodysplastic syndromes
Baricitinib 10.01.03 Formulary NICE TA466 Baricitinib for moderate to severe rheumatoid arthritis (2017)
Bendamustine 08.01.01 Formulary NICE TA216: Bendamustine for CLL
Bevacizumab 08.01.05 Formulary NICE TA214: Breast Cancer with taxane
Bevacizumab 08.01.05 Formulary NICE TA263: Breast cancer with capecitabine
Bortezomib 08.01.05 Formulary NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA129: Multiple myeloma - bortezomib
Bosutinib 08.01 Restricted Use NICE TA401 Bosutinib for previously treated chronic myeloid leukaemia (2016)
Botulinum Toxin Type A 04.09.03 Formulary NICE TA260: Botox for migraine prophylaxis
Brentuximab vedotin 08.02 Restricted Use NICE TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (2017)
Carfilzomib 08.01.05 Restricted Use NICE TA457 Carfilzomib for previously treated multiple myeloma (2017)
Ciclosporin 11.04.02 Restricted Use NICE TA369 Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Crizotinib 08.01.05 Restricted Use NICE TA406 Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (2016)
Diltiazem Cream 2% 01.07.04 Formulary Chronic anal fissure: 2% topical diltiazem hydrochloride
Fulvestrant 08.03.04.01 Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Ibrutinib 08.01.05 Restricted Use NICE TA491 Ibrutinib for treating Waldenstrom’s macroglobulinaemia (2017)
Infliximab 01.05.03 Formulary NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
Nivolumab 08.02 Restricted Use NICE TA462 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (2017)
Obinutuzumab 08.02.03 Restricted Use Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Palbociclib 08.01.05 Restricted Use NICE TA495 Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (2017)
Pimecrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Pixantrone 08.01.02 Restricted Use NICE TA 306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B‑cell lymphoma
Pomalidomide 08.02.04 Restricted Use NICE TA 427 Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (2017)
Ponatinib 08.01.05 Restricted Use NICE TA451 Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (2018)
Ribociclib 08.01.05 Restricted Use NICE TA496 Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (2017)
Sarilumab 10.01.03 Formulary NICE TA485 Sarilumab for moderate to severe rheumatoid arthritis (2017)
Sodium Zirconium Cyclosilicate 09.02.01 Formulary NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia
Tacrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tofacitinib 10.01.03 Formulary NICE TA480 Tofacitinib for moderate to severe rheumatoid arthritis (2017)
Topotecan 08.01.05 Non Formulary NICE TA91: Topotecan for ovarian cancer
Venetoclax 08.01.05 Restricted Use NICE TA487 Venetoclax for treating chronic lymphocytic leukaemia (2017)
The Rotherham